Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ARMO BioSciences, Inc. (NASDAQ: ARMO).

Full DD Report for ARMO

You must become a subscriber to view this report.


Recent News from (NASDAQ: ARMO)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of ARMO Biosciences, Inc. - ARMO
BALA CYNWYD, PA / ACCESSWIRE / May 16, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ARMO Biosciences, Inc. ("ARMO" or "the Company") (NASDAQ: ARMO News) for possible breaches of fiduciary duty and other vi...
Source: ACCESSWIRE IA
Date: May, 16 2018 21:05
Eli Lilly Had Good Reason To Spend $1.6B On Armo
Eli Lilly’s ( LLY ) $1.6 billion purchase of Armo Biosciences ( ARMO ) last week has deeper implications than simply making Armo shareholders richer. More important than that, it is a vote of confidence in an approach casting an ever wider net of combining cancer immunotherapies with an...
Source: SeekingAlpha
Date: May, 16 2018 11:24
Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With
Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come...
Source: SeekingAlpha
Date: May, 16 2018 07:38
WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders
NEW YORK , May 14, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of ARMO BioSciences Inc. ("ARMO" or the "Company") (NASDAQ: ARMO) in connection with the proposed acquisition of the Company...
Source: PR Newswire
Date: May, 14 2018 11:38
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size ...
Source: SeekingAlpha
Date: May, 14 2018 11:37
Week In Review: $3.4 Billion Week For China Life Science Deals
Deals and Financings Armo BioSciences (ARMO), a Bay Area immuno-oncology company, agreed to be acquired by Eli Lilly (LLY) in a $1.6 billion transaction. Last year, Armo raised $67 million in a 2017 Series C-1 funding from China investors. Four months ago, Armo completed a $128 million IPO...
Source: SeekingAlpha
Date: May, 13 2018 11:40
Your Daily Pharma Scoop: Our Watchlist Pick ARMO Acquired, Ziopharma Low Cash, Coherus PDUFA Date
Analysis focus: ARMO Eli Lilly (NYSE: LLY ) has agreed to acquire ARMO BioSciences for $1.6bn ($50/share) in cash. This is almost a 40% premium to ARMO’s previous closing price of $29.82. It is currently trading at $49.80. The transaction will close this quarter, helping Lilly bol...
Source: SeekingAlpha
Date: May, 11 2018 10:00
Eli Lilly Makes A Bold Acquisition; How Lucrative Is It?
Recently, Eli Lilly ( LLY ) announced that it had acquired ARMO BioSciences ( ARMO ) for approximately $1.6 billion in cash . In the end, Eli Lilly paid $50 a share which caused the stock to trade higher by 67% to $49.84 per share. This was a pretty quick run for ARMO, because it had ...
Source: SeekingAlpha
Date: May, 11 2018 00:49
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of ARMO Biosciences, Inc. - ARMO
BALA CYNWYD, PA / ACCESSWIRE / May 10, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ARMO Biosciences, Inc. ("ARMO'' or "the Company") (NASDAQ: ARMO - News) for possible breaches of fiduciary duty and other...
Source: ACCESSWIRE IA
Date: May, 10 2018 21:28
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of ARMO BioSciences, Inc. (ARMO) on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of ARMO BioSciences, Inc. (NASDAQ: ARMO) stockholders concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY). Our investigation concerns whether ARMO’s board of directors f...
Source: Business Wire
Date: May, 10 2018 16:37

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1749.8549.8049.9249.79584,582

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-06-216,15325,26324.3558Cover
2018-06-208,39922,24037.7653Short
2018-06-1928,30449,92956.6885Short
2018-06-1814,68844,61932.9187Cover
2018-06-156,77712,14155.8191Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ARMO.


About ARMO BioSciences, Inc. (NASDAQ: ARMO)

Logo for ARMO BioSciences, Inc. (NASDAQ: ARMO)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ARMO)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Written public communication relating to an issuer or third party tender offer not by the subject company
      Filing Type: SC TO-CFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Written public communication by the subject company relating to a tender offer by a third party
      Filing Type: SC14D9CFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 02 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 30 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: March, 16 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: February, 08 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: January, 30 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: January, 29 2018

       

       


      Daily Technical Chart for (NASDAQ: ARMO)

      Daily Technical Chart for (NASDAQ: ARMO)


      Stay tuned for daily updates and more on (NASDAQ: ARMO)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ARMO)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARMO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ARMO and does not buy, sell, or trade any shares of ARMO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/